August 29, 2017 07:11 AM EDT
Pharma

Jazz gam­bles $175M on a triple-pronged armed an­ti­body pact with Im­muno­Gen

John Carroll

Editor & Founder

Jazz Phar­ma­ceu­ti­cals is team­ing up with Im­muno­Gen on a slate of armed an­ti­bod­ies.

Jazz $JAZZ will pay $175 mil­lion — $75 mil­lion up­front and …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

The End­points 2024 win­ners and losers list: Who was up and who was down in bio­phar­ma

Ca­griSe­ma’s weight loss da­ta dis­ap­point­ed. What does No­vo do next?

CMS ex­plains what went in­to its first round of drug price ne­go­ti­a­tions

FDA ap­proves Lil­ly's Zep­bound for sleep ap­nea, like­ly crack­ing open Medicare mar­ket

Ex­clu­sive: Flori­da can­cer biotech rais­es $100M Se­ries A

Im­munol­o­gy biotech In­ma­gene to join Nas­daq through re­verse merg­er with what's left of Ike­na

A service from the Financial Times